In Part 2 of a two-part interview with Pharmaceutical Technology, Dexter Tjoa, CEO of Tjoapack, builds on the themes of sustainability, specialization, and digitalization by exploring how supply chain strategy is evolving heading into 2026.

Dexter explains that geopolitical rhetoric and broader market uncertainty are shifting how pharmaceutical companies approach partnerships and long-term planning. Rather than focusing solely on globally “optimal” capabilities, manufacturers are increasingly prioritizing regional support in North America and Europe. While the full impact of these shifts may take years to materialize, investment announcements and capacity expansion plans are already accelerating.

Dexter also highlights why the role of the expert packaging partner is becoming even more critical—particularly for innovative biotech companies that may not have extensive internal manufacturing networks. As the final step before distribution, packaging has a direct influence on fulfillment lead times, delivery schedules, stock strategy, and product wastage. A more strategic approach to packaging can reduce financial risk and improve reliability, ensuring that more medicine reaches patients.

Overall, the interview reinforces a key message: as supply chains become more regional and product portfolios more complex, packaging is increasingly viewed as a strategic function—not just an operational step.

📖 Read / watch the full Part 2 interview.

‍